- Patents. All of Pondera’s formulations and products are covered under a series of patents and patent applications, insuring proprietary status and patent protection against competition. On February 12, 2013 the U.S. Patent Office Issued Pat. No. 8,372,414 to Pondera for Anxiety Relief.
- Partnership and licensing Agreements. Pondera will consider entering into appropriate and mutually beneficial partnership and licensing agreements in the United States, Canada, Europe, South America, Asia and Africa for Endorphinate® commercialization.
- Manufacturing. Pondera is seeking manufacturers in the United States, Canada, Europe, South America, Asia and Africa to produce Endorphinate® for these markets.
- Distribution and sales. Pondera is seeking to establish distribution and sales relationship with companies in the United States, Canada, Europe, South America, Asia and Africa to distribute and sell Endorphinate®.
For access to Confidential Financial, Scientific, Research and Strategic Partnership Information, please contact:
William E. Crain, President & CEO
Pondera Pharmaceuticals, Inc.
209 Chadsey Road, Pownal ME 04069